The bull case for Nebius: 571% revenue growth and 4x FY 2027 revenue guidance make its 2.8x forward sales multiple look ...

Analyst rates CareCloud Neutral: its $2.80 FY 2027 target implies 7% upside after Q3's rally; wait for FY 2027 guidance.

Analyst rates ArriVent a Hold: $393 million in cash and pipeline potential support value, while clinical execution risks ...

Analyst sees GE HealthCare Technologies offering limited upside: estimated 2027 adjusted EPS of $5.30 at 16x supports an ...

Analyst rates Kura Oncology a cautious Hold: $6.75 implies roughly 10% downside, balanced by 53% Q3 KOMZIFTI sales growth and ...

Analyst rates Inter & Co a Strong Buy on 26.46% Q3 net income growth and 0.86x book, with 132.56% potential upside after a 45 ...

The bull case for Prologis preferred shares: at $49.99, they yield 8.82% and could gain if called at $50 on or after Nov.

Digi Power X has secured expansion financing plans, but dilution and future interest costs temper my previously bullish ...

Those forecasts suggest real growth, bolstered by buoyant server demand, a diversified product portfolio, and Intel's ...

The global oil market is expected to return to a surplus in Q4 for the first time since the Iran war began, as exports from ...

That's why Buy, and not Strong Buy, this time. I still believe the Brazilian market is cheap for its own history and that the ...

Analyst rates Adecoagro a Buy as valuation offers a margin of safety; Caarapó boosts integration, with a clear path to 2.5x ...